Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 3/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.40 |
| ▸ | PARP1 | P09874 | 5/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29824451 | 1.00 | TNKS (0.40) | TNKSTNKS2PARP1NFKB1NFKB2 | |
| SCHEMBL23537227 | 1.00 | TNKS (0.40) | TNKSTNKS2PARP1NFKB1NFKB2 | |
| SCHEMBL30023263 | 0.92 | PARP1 (0.43) | TNKSTNKS2PARP1NFKB1NFKB2 | |
| SCHEMBL29824425 | 0.92 | PARP1 (0.43) | TNKSTNKS2PARP1NFKB1NFKB2 | |
| SCHEMBL23537293 | 0.92 | PARP1 (0.43) | TNKSTNKS2PARP1NFKB1NFKB2 | |
| SCHEMBL29824164 | 0.92 | PARP1 (0.43) | TNKSTNKS2PARP1NFKB1NFKB2 | |
| SCHEMBL23537368 | 0.82 | PARP1 (0.44) | TNKSTNKS2PARP1TP53HPGD | |
| SCHEMBL29824222 | 0.82 | PARP1 (0.44) | TNKSTNKS2PARP1TP53HPGD | |
| SCHEMBL30023524 | 0.82 | PARP1 (0.44) | TNKSTNKS2PARP1TP53HPGD | |
| SCHEMBL23537371 | 0.81 | TNKS (0.43) | TNKSTNKS2PARP1NFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230108906-A1 | SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2023-04-06 | — | — | US | disclosed |
| EP-4076648-A1 | SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | Arbutus Biopharma Corporation (CA) | 2022-10-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230108906-A1 | SUBSTITUTED BICYCLIC AND TRICYCLIC UREAS AND AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | DDC, CDA, HMBS | TNKS 2559/4885TNKS2 3385/4885PARP1 2241/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.